SCHEMBL15340753

SCHEMBL15340753

Cc1nc(C2CCN(c3ccc(C(F)(F)F)cn3)CC2)sc1COc1ccc(-n2cnnn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 10/20 0.49
KCNH2 Q12809 3/20 0.40
SMO Q99835 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ABL1 P00519 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX15 P16050 1/20 0.36
KMT2A Q03164 1/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118357 0.91 GPR119 (0.58) GPR119KCNH2MAPTMEN1ALDH1A1
SCHEMBL1118349 0.85 GPR119 (0.66) GPR119KCNH2SMOKDM4EABL1
SCHEMBL3489655 0.79 GPR119 (0.47) GPR119MAPTHPGDL3MBTL1MEN1
Hydrochloric Acid SCHEMBL3487947 0.78 GPR119 (0.47) GPR119MAPTHPGDMEN1ALDH1A1
SCHEMBL1118325 0.77 GPR119 (0.74) GPR119MAPTMEN1ALDH1A1ALOX15
SCHEMBL1118496 0.77 GPR119 (0.72) GPR119SMN1; SMN2MAPTMEN1ALDH1A1
SCHEMBL11885630 0.76 GPR119 (0.58) GPR119KCNH2MEN1ALDH1A1ALOX15
SCHEMBL11885634 0.75 GPR119 (0.78) GPR119KCNH2
SCHEMBL3489310 0.72 GPR119 (0.73) GPR119MAPTHPGDMEN1ALDH1A1
SCHEMBL1118410 0.72 GPR119 (0.62) GPR119KDM4ELMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281691-A1 HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS CYMABAY THERAPEUTICS, INC. 2013-10-24 US disclosed
US-20130281691-A1 HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS CYMABAY THERAPEUTICS, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281691-A1 HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS GPR119, INSR, GLP1R GPR119 1/4885KCNH2 1290/4885SMO 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.